{'fraction_non_alphanumeric': 0.0186799501867995, 'fraction_numerical': 0.014943960149439602, 'mean_word_length': 5.483870967741935, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Type 2 diabetes management.

In May 2009, the National Institute for Health and Clinical Excellence published new guidance on the management of type 2 diabetes. The guidance offered a blueprint for when, and to which patients, newer antidiabetic medicines (eg, incretin mimetics, thiazolidinediones) should be offered. The Scottish Intercollegiate Guideline Network published guidelines on the management of diabetes in 2001 but these do not offer detailed recommendations for type 2 diabetes treatment or on glycaemic control and are not recent enough to include some of the newer medicines. This article summarises the available pharmacological treatments for people with type 2 diabetes, in the context of the recent NICE recommendations (although insulin treatment is not discussed in great detail).